Biogen Inc. stock underperforms Friday when compared to competitors
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Fifth Third Bancorp
Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...
FierceBiotech9d
Biogen research team hit by layoffs as company shifts resources to external opportunities
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it ...
Exchange Traded Concepts LLC Boosts Position in Biogen Inc. (NASDAQ:BIIB)
Exchange Traded Concepts LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.5% during the 4th ...
FiercePharma10d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
Biogen (BIIB) Gets a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Biogen CEO tells Governor Healey he’s concerned about ‘a lot more policy risk’ in D.C.
Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...
BioSpace10h
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...